Since IL-6 activation in subcutaneous adipose tissue may induce leptin-mediated GLP-1 release [202], and GLP-1 potentiates glucose-stimulated insulin release, selective IL-6 activation could be a beneficial strategy to prevent the development of T2D in insulin-resistant patients. The gene discussed is IL6; the disease is type 2 diabetes mellitus.